Dara Biosciences Inc (DARA) financial statements (2023 and earlier)
Company profile
| Business Address |
8601 SIX FORKS ROAD SUITE 160 RALEIGH, NC 27615 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2014 | 12/31/2013 | 12/31/2012 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 12,027 | 3,426 | 6,593 | ||
| Cash and cash equivalents | 12,027 | 3,426 | 6,496 | ||
| Short-term investments | 96 | ||||
| Receivables | 1,355 | 174 | 173 | ||
| Inventory, net of allowances, customer advances and progress billings | 265 | 104 | 125 | ||
| Inventory | 265 | 104 | 125 | ||
| Prepaid expense and other current assets | ✕ | ✕ | 153 | ||
| Other undisclosed current assets | 127 | 185 | |||
| Total current assets: | 13,774 | 3,889 | 7,045 | ||
| Noncurrent Assets | |||||
| Property, plant and equipment | 36 | 41 | 50 | ||
| Intangible assets, net (including goodwill) | 3,930 | 4,046 | 4,530 | ||
| Goodwill | 821 | 821 | 821 | ||
| Intangible assets, net (excluding goodwill) | 3,109 | 3,225 | 3,709 | ||
| Restricted cash and investments | 13 | 13 | 13 | ||
| Prepaid expense and other noncurrent assets | ✕ | ✕ | 54 | ||
| Total noncurrent assets: | 3,979 | 4,099 | 4,647 | ||
| TOTAL ASSETS: | 17,752 | 7,988 | 11,692 | ||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,306 | 1,529 | 1,882 | ||
| Accounts payable | 483 | 620 | 1,383 | ||
| Accrued liabilities | 1,170 | 785 | 327 | ||
| Employee-related liabilities | 653 | 124 | 172 | ||
| Debt | 7 | 4 | 7 | ||
| Other undisclosed current liabilities | 1,432 | 142 | 150 | ||
| Total current liabilities: | 3,745 | 1,675 | 2,039 | ||
| Noncurrent Liabilities | |||||
| Long-term debt and lease obligation | 22 | 16 | 20 | ||
| Capital lease obligations | 22 | 16 | 20 | ||
| Liabilities, other than long-term debt | 69 | 73 | 41 | ||
| Deferred revenue and credits | 69 | 73 | 41 | ||
| Other undisclosed noncurrent liabilities | 662 | 599 | |||
| Total noncurrent liabilities: | 91 | 751 | 660 | ||
| Total liabilities: | 3,836 | 2,426 | 2,699 | ||
| Stockholders' equity | |||||
| Stockholders' equity attributable to parent, including: | 13,916 | 6,609 | 9,638 | ||
| Preferred stock | 0 | ||||
| Common stock | 198 | 310 | 189 | ||
| Additional paid in capital | 79,712 | 63,292 | 56,430 | ||
| Accumulated other comprehensive income | 45 | ||||
| Accumulated deficit | (65,994) | (56,993) | (47,028) | ||
| Other undisclosed stockholders' equity attributable to parent | 0 | 0 | 0 | ||
| Stockholders' equity attributable to noncontrolling interest | (1,047) | (645) | |||
| Total stockholders' equity: | 13,916 | 5,562 | 8,993 | ||
| TOTAL LIABILITIES AND EQUITY: | 17,752 | 7,988 | 11,692 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|
| Revenues | 1,887 | 419 | 54 | |
| Revenue, net | 54 | |||
| Cost of revenue (Cost of Goods and Services Sold) | (708) | (219) | (24) | |
| Gross profit: | 1,178 | 200 | 30 | |
| Operating expenses | (11,287) | (10,690) | (9,667) | |
| Other undisclosed operating income | 708 | |||
| Operating loss: | (9,400) | (10,489) | (9,637) | |
| Nonoperating income | 163 | 150 | 597 | |
| Other nonoperating income | 228 | 145 | ||
| Interest and debt expense | (67) | (12) | ||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 12 | |||
| Loss from continuing operations before equity method investments, income taxes: | (9,237) | (10,406) | (9,040) | |
| Other undisclosed income from continuing operations before income taxes | 67 | |||
| Loss from continuing operations before income taxes: | (9,237) | (10,339) | (9,040) | |
| Income tax expense (benefit) | (29) | 1,300 | ||
| Net loss: | (9,237) | (10,368) | (7,740) | |
| Net income attributable to noncontrolling interest | 236 | 403 | 429 | |
| Net loss available to common stockholders, diluted: | (9,001) | (9,965) | (7,311) | |
Comprehensive Income ($ in thousands)
| 12/31/2014 | 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|---|
| Net loss: | (9,237) | (10,368) | (7,740) | |
| Other comprehensive income | 45 | |||
| Other undisclosed comprehensive income | 8,124 | |||
| Comprehensive income (loss): | (9,237) | (10,368) | 429 | |
| Comprehensive income (loss), net of tax, attributable to noncontrolling interest | 236 | 403 | (429) | |
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 9,920 | (7,695) | ||
| Comprehensive loss, net of tax, attributable to parent: | (9,001) | (45) | (7,695) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.